Drugs / MSP3 Long Synthetic Peptide
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00452088 | Apr 2007 → May 2008 | malaria | African Malaria Network Trust | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00652275 | May 2008 → Nov 2010 | Plasmodium falciparum malaria | African Malaria Network Trust | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSP 3 Long Synthetic Peptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00452088 ↗ |
| Known as | MSP3 LSP | “MSP3 Long Synthetic Peptide 30 micrograms of MSP3 LSP” NCT00652275 ↗ |
| Modality | Vaccine | “This will be a study of the safety of MSP 3 LSP candidate malaria vaccine in children aged 1-2 years in Burkina Faso.” NCT00452088 ↗ |
| Route | Subcutaneous | “Three imminizations at 28 day intervals will be administratered subcuteneously on the shoulder region.” NCT00452088 ↗ |